Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3714418 | 0.78 | CYP2A6 (0.64) | CYP2A6FLT3TYRDAOAKR1B1 | |
| SCHEMBL4816114 | 0.78 | CYP2A6 (0.64) | CYP2A6FLT3TYRDAOAKR1B1 | |
| SCHEMBL30142419 | 0.78 | CYP2A6 (1.00) | CYP2A6FLT3TYRDAOAKR1B1 | |
| SCHEMBL2855183 | 0.78 | CYP2A6 (0.64) | CYP2A6FLT3TYRDAOAKR1B1 | |
| SCHEMBL1778078 | 0.78 | CYP2A6 (0.64) | CYP2A6FLT3TYRDAOAKR1B1 | |
| SCHEMBL846924 | 0.78 | CYP2A6 (1.00) | CYP2A6FLT3TYRDAOAKR1B1 | |
| SCHEMBL18253195 | 0.75 | CYP2A6 (0.60) | CYP2A6FLT3TYRDAOAKR1B1 | |
| SCHEMBL23859796 | 0.74 | MAOB (0.55) | SMN1; SMN2CA2MAOBKDM4ERAB9A | |
| SCHEMBL2229964 | 0.74 | HPGD (0.56) | TYRDAOAKR1B1HPGDPOLB | |
| SCHEMBL5327160 | 0.74 | CYP2A6 (0.58) | CYP2A6FLT3TYRDAOAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1689 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356387-B1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | UNIV MONASH (AU) | 2024-06-26 | — | — | EP | claimed |
| CN-114369178-A | Photoinitiating composition, photocuring composition, photoresist, photocuring composition and application of photoresist | 江苏英力科技发展有限公司 | 2022-04-19 | — | — | CN | claimed |
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | MONASH UNIVERSITY (AU) | 2022-01-18 | — | — | US | claimed |
| CN-111689989-B | Containing SO2Polyheterocyclic compounds and uses thereof | 北京燕化集联光电技术有限公司 | 2021-11-02 | — | — | CN | claimed |
| CN-111662298-B | Compound containing multiple heterocyclic rings and application thereof in organic electroluminescent device | 北京燕化集联光电技术有限公司 | 2021-08-10 | — | — | CN | claimed |
| US-20180282374-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | MONASH UNIVERSITY (AU) | 2018-10-04 | — | — | US | claimed |
| EP-3356387-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | Monash University (AU) | 2018-08-08 | — | — | EP | claimed |
| US-9896452-B2 | Substituted prolines/piperidines as orexin receptor antagonists | EOLAS THERAPEUTICS, INC. (US) | 2018-02-20 | — | — | US | claimed |
| CN-106831755-A | Benzamide compound and its salt form and purposes | 阿腾弩阿公司 | 2017-06-13 | — | — | CN | claimed |
| US-20170101410-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | EOLAS THERAPEUTICS, INC. | 2017-04-13 | — | — | US | claimed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | claimed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | claimed |
| US-4727060-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1988-02-23 | — | — | US | claimed |
| EP-0184550-A2 | 5-Amino-4-hydroxy valeryl amide derivatives | CIBA-GEIGY AG (CH) | 1986-06-11 | — | — | EP | claimed |
| EP-0053893-B1 | DERIVATIVES OF CLAVULANIC ACID, THEIR PREPARATION AND THEIR USE | BEECHAM GROUP PLC (GB) | 1985-03-20 | — | — | EP | claimed |
| EP-0000599-B1 | ELECTRICALLY PHOTOSENSITIVE PARTICLES FOR PHOTOELECTROPHORETIC MIGRATION IMAGING PROCESSES | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1983-02-02 | — | — | EP | claimed |
| US-4293626-A | ORGANIC PIGMENT | EASTMAN KODAK COMPANY (US) | 1981-10-06 | — | — | US | claimed |
| US-4272595-A | UNSATURATED NITRILE | EASTMAN KODAK COMPANY (US) | 1981-06-09 | — | — | US | claimed |
| US-4256819-A | MEROCYANINES | EASTMAN KODAK COMPANY (US) | 1981-03-17 | — | — | US | claimed |
| EP-0000599-A1 | Electrically photosensitive particles for photoelectrophoretic migration imaging processes | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1979-02-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | VIP, PNKP, PEPD | CYP2A6 4500/4885FLT3 1197/4885TYR 4595/4885 |
| US-20170101410-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OPRL1 | CYP2A6 2520/4885FLT3 2017/4885TYR 1539/4885 |
| US-20180282374-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | VIP, PNKP, PEPD | CYP2A6 4500/4885FLT3 1197/4885TYR 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.